BioCentury
ARTICLE | Clinical News

Alpha galactosidase: Additional Phase I/II data

September 19, 2016 7:00 AM UTC

Data from 16 treatment-naive patients with Fabry’s disease in an open-label, dose-escalation, international Phase I/II trial showed that 0.2, 1 and 2 mg/kg IV PRX-102 given every 2 weeks reduced the m...